GPC1 and urothelial carcinoma: It was found that the monoclonal antibody MIL-38 holds promise for diagnosis, drug delivery and targeted therapy, as it mediated the targeted binding of upconversion photoluminescent nanoconjugates to Glypican-1 positive urothelial carcinoma cells.